A Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase I clinical trials that takes into account\npatients heterogeneity thought to be related to treatment susceptibility is described. The estimation of the maximum tolerated dose\n(MTD) curve is a function of a baseline covariate using two cytotoxic agents. A logistic model is used to describe the relationship\nbetween the doses, baseline covariate, and the probability of dose limiting toxicity (DLT). Trial design proceeds by treating cohorts\nof two patients simultaneously using escalation with overdose control (EWOC), where at each stage of the trial, the next dose\ncombination corresponds to the..............
Loading....